HIV vaccine from GeoVax Labs advances in clinical trials

GeoVax Labs' vaccine candidate for HIV has advanced to the next stage of clinical trials, the laboratory announced on Tuesday.

In this trial, 100 individual volunteers who had participated in a previous trial, concluded in 2012, will be utilized to test the vaccine candidate's efficacy for increasing antibodies in late immune system boosts. The test will determine whether the gp120 protein vaccine will act in tandem with the candidate in providing the necessary immunological boost. According to the report, the protein was successful in facilitating antibody formation in a trial of the RV144 vaccine candidate in Thailand.

"Protein boosts were important for the one partially successful HIV vaccine trial, RV144, and we will be testing the effect of the same boost used in RV144 on our vaccine," GeoVax CSO Harriet Robinson said. "We believe the HVTN (HIV Vaccine Trials Network) and its funding agency, the National Institute of Allergy and Infectious Disease (NIAID), are taking the prudent step to evaluate the impact of protein boosts in combination with GeoVax vaccines. Information from this trial will inform the design of future, larger clinical trials. We are pleased that HVTN approved the concept protocol for HVTN 114, and we look forward to taking the steps necessary for initiation of the trial and commencement of patient enrollment."

The objectives that the company has laid out for this trial are to see if the candidate and protein booster are safe to be used and to determine whether or not they are effective after a long period without immunologic activity.

Organizations in this Story

Geovax, Inc.

Want to get notified whenever we write about Geovax, Inc. ?
Next time we write about Geovax, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.